A Phase 4 interventional study of Dexmedetomidine and Placebo in Pain, Postoperative, sponsored by First People's Hospital of Chenzhou. Status unknown at 1 site in China. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-18.
Sponsored by First People's Hospital of Chenzhou · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 136 studies testing dexmedetomidine in Pain, Postoperative — 35 open to participants now, 38 under way, 5 of them phase 3. Dexmedetomidine · Pain, Postoperative.
Among the 136 studies testing dexmedetomidine in Pain, Postoperative, this one is the 69th largest by planned enrollment, is one of 13 that started in 2022, is one of 49 in phase 4, and was the 73rd registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →35 of the 136 studies testing dexmedetomidine in Pain, Postoperative are open now, in 9 countries. Recruiting first, the newest first:
Minia University · Sites in Egypt
Ages 18–70
Vasiliki Samartzi · Sites in Greece
Ages 20–70 · Women only
Tanta University · Sites in Egypt
Ages 21–60
Beijing Tiantan Hospital · Sites in China
Ages 18–65
Rhode Island Hospital · Sites in United States
Ages 18–80
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years to 50 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
136 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 24 · Phase 3 23 · Phase 4 49
First in 2008; this study’s year is marked. 13 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is close to the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 85 across the 136 interventional studies. Of the 70 that completed or were terminated, 8 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 136 have an industry lead sponsor. The 10 most frequent:
First People's Hospital of Chenzhou is the lead sponsor of 13 studies on the registry; 4 are open to participants now.
First People's Hospital of Chenzhou has 1 study filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
15 of the studies testing dexmedetomidine in Pain, Postoperative that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07878156Phase 3Children's Cancer Hospital Egypt 57357Dexmedetomidine Use for Greater Occipital Nerve Block in Pediatric Posterior Fossa Tumor Surgery. | 2026-12-30 |
| NCT07434310Phase 3Dr. Naveed SiddiquiUse of Dexmedetomidine to Improve Pain Control and Recovery After Laparocopic-Assisted Bowel Surgery in Adults | 2027-07-01 |
| NCT07847047Phase 3Assiut UniversitySafety and Efficacy of Dexamethasone Versus Dexmedetomidine as Adjuvants in PENG Block in Hip Surgeries for Postoperative Pain Management | 2027-10 |
| NCT07846722Vasiliki SamartziEsmolol Versus Dexmedetomidine for Opioid-sparing in Laparoscopic Gynecological Surgery | 2026-12-01 |
| NCT07099222University of ArizonaEfficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 136 studies testing dexmedetomidine in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to make sure whether the infiltration of dexmedetomidine around the uterus can reduce the pain of cesarean section surgery.Studies have shown that the use of local anesthetic infiltration around the uterus can reduce pain after cesarean section surgery.In observed group, 50ug of dexmedetomidine (volume 10ml) was infiltrated around the uterus at the end of the caesarean section, while in controled group, 10ml normal saline as placebo was infiltrated around the uterus. VASs was accessed in 2h 12h,24h,48h after surgery.
Cesarean section is one of the most common inpatient surgical procedures in the world, and in China, with the implementation of the comprehensive two-child policy, the number of elderly mothers and patients undergoing another cesarean section has gradually increased, and the cesarean section rate has also gradually increased; however, despite the many measures taken to control post-cesarean pain, there are still many people with inadequate pain control. Pain after cesarean delivery can have a significant negative impact on both the physical and psychological aspects of the mother and lead to complications such as thromboembolism, chronic pain and depression. Currently, a variety of methods are available to relieve post-cesarean pain, such as patient controlled intravenous analgesia (PCIA), patient controlled epidural analgesia (PCEA), transversus abdominis plane block (TAPB), etc. However, these analgesic methods are not perfect, and each has its own shortcomings. The currently prevalent ERAS concept focuses on multimodal analgesia and minimizing the use of opioids to reduce perioperative stress and reduce opioid nociceptive allergy. Compared to the technical difficulties, risks and other potential complications, abdominal medication has some advantages.
Intraperitoneal spray of local anesthetic (IPLA) has become a commonly used method of analgesia after laparotomy. Intraperitoneal administration is simple, safe, and can relieve postoperative pain, shorten the length of hospital stay, and improve comfort.
One study showed that the use of intraperitoneal infusion of lidocaine (400 mg) improved pain management in the early postoperative period after cesarean section and reduced the number of patients requiring systemic opioids in the immediate postpartum period. It has also been demonstrated that in patients undergoing bariatric surgery, intraoperative intraperitoneal spraying of ropivacaine resulted in effective postoperative pain relief, less need for morphine postoperatively, earlier activity and feeding, and shorter hospital stays, that effective pain control encouraged early bedtime, reduced the risk of thrombosis, and reduced pulmonary complications such as atelectasis or pneumonia, and that 24-hour postoperative blood counts showed significantly lower leukocyte counts were significantly lower.
Dexmedetomidine is a potent, multifunctional, highly selective α2-adrenergic agonist. It has been shown in the literature that the application of dexmedetomidine can effectively reduce the perioperative stress response, significantly reduce the dosage of opioids in the perioperative period and prevent the transformation of acute postoperative pain into chronic pain. Some animal experiments have shown that dexmedetomidine alone has obvious analgesic effect when sprayed intraperitoneally with 12.5μg/kg of dexmedetomidine, the peak time is 20-30 minutes after administration, and the duration of action is 90 minutes. There are few studies on the use of dexmedetomidine alone intraperitoneally to reduce postoperative pain in the clinical setting and there is a lack of data to support its use in post-caesarean pain.
The purpose of this study was to assess the effect of intraperitoneal dexmedetomidine 50μg at the end of cesarean delivery on maternal pain scores and satisfaction in the context of a multimodal analgesic protocol.
The investigators hypothesized that intraperitoneal dexmedetomidine would reduce VAS pain scores, reduce the number of patient-administered intravenous analgesic pump uses and opioid-related side effects, and increase maternal satisfaction after cesarean delivery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intraperitoneal instillation of normal saline
Drug: Placebo
Intraperitoneal instillation Dexmedetomidine 5ug/ml (10ml,50ug)
Drug: Dexmedetomidine
Dexmedetomidine 0.0005%
Also known as: Dexmedetomidine Hydrochloride
0.9% Sodium Chloride Solution
Also known as: Normal saline
Pain Score (VAS) 48hr rest
VAS score (VAS 0-10 cm) for maternal pain on rest at 48 hours postcesarean delivery
Time frame: 48 hours
Pain Score (VAS) 48hr movement
VAS score (VAS 0-10 cm) for maternal pain on movement at 48 hours postcesarean delivery
Time frame: 48 hours
Pain Score (VAS) 2hr rest
VAS score (VAS 0-10 cm) for maternal pain on rest at 2 hours postcesarean delivery
Time frame: 2 hours
Pain Score (VAS) 2hr movement
VAS score (VAS 0-10 cm) for maternal pain on movement at 2 hours postcesarean delivery
Time frame: 2 hours
Pain Score (VAS) 24hr rest
VAS score (VAS 0-10 cm) for maternal pain on rest at 24 hours postcesarean delivery
Time frame: 24 hours
Pain Score (VAS) 24hr movement
VAS score (VAS 0-10 cm) for maternal pain on movement at 24 hours postcesarean delivery
Time frame: 24 hours
Effective presses of PCIA pump 48hrs
Number of effective presses of PCIA pump at 48 hours postcesarean delivery
Time frame: 48 hours
Patient satisfaction 48hrs
Patient satisfaction at 48 hours postcesarean
Time frame: 48 hours
Bowel function
Return of bowel function as assessed by passing flatus
Time frame: 48 hours
Side Effect scores
Nausea, vomiting and pruritis score at 24 hours and 48 hours postcesarean delivery
Time frame: 48 hours
Flurbiprofen Axetil consumption 48hrs
Flurbiprofen Axetil consumption within 48 hours postcesarean delivery
Time frame: 48 hours
Start is estimated for Dec 2022; primary completion for Mar 2023, 3 months later.
Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 3 months is below that.
Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
First People's Hospital of Chenzhou